Mesoblast in Freefall, page-465

So, apparently is costs an average of US2.1B to develop a new drug to Phase 3. Does any one of the financial numbers analysts who frequent MSB forums to protect the mum's'dads want to quote MSB's accumulated losses to date (again) for their 3 drugs?

I think their lack of experience in understanding biotech development companies along with their track records in this space will inform the value of their opinion. Now, if they even had the slightest clue, they may understand a step change in treatment paradigm which a trail blazer like Mesoblast is attempting to do, will cost even more than old generation drug development.

For the real

The two key phases for FDA approval are phases 2 and 3, outlined on the FDA’s website, where drugs begin animal and human testing. Phase 3 trials are especially important and are typically the most expensive - The average cost of developing a new drug is estimated at more than US2.1bn.

https://www.livewiremarkets.com/wires/the-lifecycle-of-a-biotech